Safety and Efficacy Study of Pitavastatin in Patient With a Metabolic Syndrome (ProPit)
A Prospective Comparative Clinical Study to Identify Efficacy and Safety of Pitavastatin in Patients With a Metabolic Syndrome
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Gyeonggi-do
-
Bundang-gu, Gyeonggi-do, Korea, Republic of, 463-707
- Seoul National University Bundang Hospital
-
Guri-si, Gyeonggi-do, Korea, Republic of, 471-701
- Hanyang Univ. Guri Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged between 18 and 75
- Patients with LDL ≥ 100mg/dL
Patients with metabolic syndrome
- IFG: Fasting glucose ≥ 100mg/dL
- Abdominal Obesity: Waist circumference: men≥90cm,women≥85cm
1 or more of the following
- Triglyceride ≥ 150mg/dL
- HDL-C: men < 40mg/dL, women < 50mg/dL
- Blood pressure: SBP ≥ 130mmHg or DBP ≥ 85mmHg or subject receiving anti-hypertensive treatment
Exclusion Criteria:
- uncontrolled hypertension (DBP ≥ 95mmHg)
- taking diabetic drugs or with HbA1c > 8%
- LDL ≥ 190mg/dL or Triglyceride ≥ 400mg/dL
- coronary heart disease or other diseases caused by artherosclerosis
- malignancy within 6 months
- Serum creatinine ≥ 2.0mg/dL
- ALT or AST ≥ ULN*2.5
- CPK ≥ ULN*2
- hypothyroidism
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: T
Lifestyle modification + active drug(Pitavastatin)
|
Pitavastatin 2mg daily once
Other Names:
|
|
Other: C
Lifestyle Modification
|
conducting mainly exercises and diet
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
A change of metabolic syndrome risk component
Time Frame: 48week
|
48week
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Changes of cardiometabolic profiles : lipid profiles, hs-CRP, adiponectin, HMW adiponectin
Time Frame: 48week
|
48week
|
|
Changes of abdominal visceral fat
Time Frame: 48week
|
48week
|
|
Changes of insulin resistance : OGTT(75g), HOMA
Time Frame: 48week
|
48week
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Chang Beom Lee, Hanyang Univ. Guri Hospital
- Study Chair: Hak Chul Jang, Seoul National University Bundang Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Glucose Metabolism Disorders
- Metabolic Diseases
- Disease
- Insulin Resistance
- Hyperinsulinism
- Lipid Metabolism Disorders
- Hyperlipidemias
- Dyslipidemias
- Syndrome
- Metabolic Syndrome
- Hypercholesterolemia
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Pitavastatin
Other Study ID Numbers
Other Study ID Numbers
- CWP_PTV_706
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.